Please use this identifier to cite or link to this item:
Title: A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
Authors: Shan, Sisi
Mok, Chee Keng 
Zhang, Shuyuan
Lan, Jun
Li, Jizhou
Yang, Ziqing
Wang, Ruoke
Cheng, Lin
Fang, Mengqi
Aw, Zhen Qin 
Yu, Jinfang
Zhang, Qi
Shi, Xuanling
Zhang, Tong
Zhang, Zheng
Wang, Jianbin
Wang, Xinquan
Chu, Justin Jang Hann 
Zhang, Linqi
Keywords: epitope
human neutralizing antibody
in vivo protection
variants of concern
Issue Date: 13-Dec-2021
Publisher: Frontiers Media S.A.
Citation: Shan, Sisi, Mok, Chee Keng, Zhang, Shuyuan, Lan, Jun, Li, Jizhou, Yang, Ziqing, Wang, Ruoke, Cheng, Lin, Fang, Mengqi, Aw, Zhen Qin, Yu, Jinfang, Zhang, Qi, Shi, Xuanling, Zhang, Tong, Zhang, Zheng, Wang, Jianbin, Wang, Xinquan, Chu, Justin Jang Hann, Zhang, Linqi (2021-12-13). A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants. Frontiers in Immunology 12 : 766821. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge and spread around the world, antibodies and vaccines to confer broad and potent neutralizing activity are urgently needed. Through the isolation and characterization of monoclonal antibodies (mAbs) from individuals infected with SARS-CoV-2, we identified one antibody, P36-5D2, capable of neutralizing the major SARS-CoV-2 variants of concern. Crystal and electron cryo-microscopy (cryo-EM) structure analyses revealed that P36-5D2 targeted to a conserved epitope on the receptor-binding domain of the spike protein, withstanding the three key mutations—K417N, E484K, and N501Y—found in the variants that are responsible for escape from many potent neutralizing mAbs, including some already approved for emergency use authorization (EUA). A single intraperitoneal (IP) injection of P36-5D2 as a prophylactic treatment completely protected animals from challenge of infectious SARS-CoV-2 Alpha and Beta. Treated animals manifested normal body weight and were devoid of infection-associated death up to 14 days. A substantial decrease of the infectious virus in the lungs and brain, as well as reduced lung pathology, was found in these animals compared to the controls. Thus, P36-5D2 represents a new and desirable human antibody against the current and emerging SARS-CoV-2 variants. Copyright © 2021 Shan, Mok, Zhang, Lan, Li, Yang, Wang, Cheng, Fang, Aw, Yu, Zhang, Shi, Zhang, Zhang, Wang, Wang, Chu and Zhang.
Source Title: Frontiers in Immunology
ISSN: 1664-3224
DOI: 10.3389/fimmu.2021.766821
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3389_fimmu_2021_766821.pdf8.92 MBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons